List view / Grid view
16 October 2014 | By METTLER TOLEDO
The new line of XPE balances focuses on delivering accurate, compliant results and provides users with a high level of process security, suitable for even the strictest regulations...
16 October 2014 | By Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. announced its new wholly owned subsidiary in Italy...
16 October 2014 | By Roche
Roche announce Q3 2014 results...
16 October 2014 | By GlobalData
In the battle against Ebola, incentives from governments and healthcare policymakers have been and will continue to be vital for advancing the current treatment pipeline, by mitigating the risk and up-front costs from pharmaceutical companies, says an analyst with research and consulting firm GlobalData...
16 October 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has approved Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis in the United States...
15 October 2014 | By Coulter Partners
Coulter Partners, the Global Life sciences search specialist, is delighted to announce the appointment of Tobias (Toby) Ernberg as Executive Vice President...
15 October 2014 | By Promethera Biosciences
HEP002 trial represents the world’s first Phase IIb/III trial with a stem cell-based medicinal product for the treatment of urea cycle disorders patients...
15 October 2014 | By Auspherix & Domainex
Domainex Ltd. and Auspherix Pty Ltd announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate...
14 October 2014 | By GlobalData
The Netherlands’ pharmaceutical market value will rise slowly from approximately $6.7 billion in 2014 to $7.2 billion by 2020, with growth restricted by the government’s focus on generic drugs as a cost-containment tool, according to research and consulting firm GlobalData...
14 October 2014 | By Imaxio
Imaxio’s pro-immunogenic technology will be tested to enhance the efficacy of a candidate vaccine for the human papillomavirus (HPV)...
14 October 2014 | By Pharmalink
Pharmalink AB, a specialty pharma company focused on orphan and niche products, has elected Bengt Julander as Chairman of the Board of Directors...
14 October 2014 | By Janssen
Persistence of STELARA® (ustekinumab) significantly better than anti-TNFs in treatment of psoriasis according to observational study analysis...
14 October 2014 | By New Oncology
New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris...
14 October 2014 | By Rigontec GmbH
Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the first closing of its Series A financing round, raising €9.45 million...
14 October 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure® in Switzerland...
